Published in Curr Neuropharmacol on March 01, 2012
A further update on the role of excitotoxicity in the pathogenesis of Parkinson's disease. J Neural Transm (Vienna) (2014) 0.84
Metabotropic glutamate receptors for Parkinson's disease therapy. Parkinsons Dis (2013) 0.82
Synthesis and preliminary studies of a novel negative allosteric modulator [(11)C]QCA for imaging of metabotropic glutamate receptor 2. ACS Chem Neurosci (2017) 0.81
Neuroprotective effect of penehyclidine hydrochloride on focal cerebral ischemia-reperfusion injury. Neural Regen Res (2013) 0.79
Hypo-anxious phenotype of adolescent offspring prenatally exposed to LPS is associated with reduced mGluR5 expression in hippocampus. Open J Med Psychol (2014) 0.78
Lentivirus mediated siRNA against GluN2B subunit of NMDA receptor reduces nociception in a rat model of neuropathic pain. Biomed Res Int (2014) 0.77
Maternal inflammation leads to impaired glutamate homeostasis and up-regulation of glutamate carboxypeptidase II in activated microglia in the fetal/newborn rabbit brain. Neurobiol Dis (2016) 0.76
Metabotropic Glutamate Receptors and Interacting Proteins in Epileptogenesis. Curr Neuropharmacol (2016) 0.75
mGluR-LTD at Excitatory and Inhibitory Synapses in the Lateral Habenula Tunes Neuronal Output. Cell Rep (2016) 0.75
Loss of Metabotropic Glutamate Receptor 5 Function on Peripheral Benzodiazepine Receptor in Mice Prenatally Exposed to LPS. PLoS One (2015) 0.75
LTP and LTD: an embarrassment of riches. Neuron (2004) 15.48
Parkinson's disease: mechanisms and models. Neuron (2003) 14.84
Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol (1997) 10.26
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry (1994) 8.88
The mGluR theory of fragile X mental retardation. Trends Neurosci (2004) 8.88
Epidemiology of Parkinson's disease. Lancet Neurol (2006) 8.13
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med (2007) 7.24
Huntington disease. J Neuropathol Exp Neurol (1998) 6.54
Correction of fragile X syndrome in mice. Neuron (2007) 6.51
Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci U S A (2002) 6.45
Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci (1991) 5.71
The metabotropic glutamate receptors: structure and functions. Neuropharmacology (1995) 5.11
Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits. Proc Natl Acad Sci U S A (1997) 4.73
Schizophrenia. Lancet (2004) 4.70
Fmr1 knockout mice: a model to study fragile X mental retardation. The Dutch-Belgian Fragile X Consortium. Cell (1994) 4.43
Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron (2001) 4.15
Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron (2005) 4.11
Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology (2005) 4.09
Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry (2010) 4.00
FMR1 and the fragile X syndrome: human genome epidemiology review. Genet Med (2001) 3.84
Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: a quantitative examination. Am J Med Genet (2001) 3.77
Dysregulation of mTOR signaling in fragile X syndrome. J Neurosci (2010) 3.73
Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science (1998) 3.70
Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. J Neurosci (1997) 3.49
Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am J Psychiatry (2006) 3.47
From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome. Nat Rev Neurosci (2005) 3.46
The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol (1994) 3.42
Motor deficit and impairment of synaptic plasticity in mice lacking mGluR1. Nature (1994) 3.33
Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev (2005) 3.32
The amygdala and persistent pain. Neuroscientist (2004) 3.24
Perisynaptic location of metabotropic glutamate receptors mGluR1 and mGluR5 on dendrites and dendritic spines in the rat hippocampus. Eur J Neurosci (1996) 3.22
Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. J Neurosci (2005) 3.08
Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet (1995) 3.06
Sequence and expression of a metabotropic glutamate receptor. Nature (1991) 2.97
Metabotropic glutamate receptors: electrophysiological properties and role in plasticity. Brain Res Brain Res Rev (1999) 2.95
Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J Neurosci (1997) 2.89
Huntingtin-protein interactions and the pathogenesis of Huntington's disease. Trends Genet (2004) 2.88
Molecular characterization of a novel retinal metabotropic glutamate receptor mGluR6 with a high agonist selectivity for L-2-amino-4-phosphonobutyrate. J Biol Chem (1993) 2.80
A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet (2009) 2.76
Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations. Arch Neurol (2006) 2.73
Analysis of neocortex in three males with the fragile X syndrome. Am J Med Genet (1991) 2.70
Metabotropic receptor-dependent long-term depression persists in the absence of protein synthesis in the mouse model of fragile X syndrome. J Neurophysiol (2006) 2.57
Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol Dis (2008) 2.52
Startle reactivity and anxiety disorders: aversive conditioning, context, and neurobiology. Biol Psychiatry (2002) 2.49
Utility of the lethargic (lh/lh) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures. Epilepsia (1997) 2.48
Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H- pyrazol-5-yl)benzamides that potentiate receptor function in vivo. J Med Chem (2004) 2.46
Role of NMDA receptors in dopamine neurons for plasticity and addictive behaviors. Neuron (2008) 2.41
Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci U S A (2004) 2.36
Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J Comp Neurol (1995) 2.29
Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl) (2005) 2.25
N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease. Prog Neurobiol (2006) 2.25
A role of ventral tegmental area glutamate in contextual cue-induced relapse to heroin seeking. J Neurosci (2004) 2.23
Altered anxiety-related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome. Genes Brain Behav (2005) 2.22
Molecular characterization of a novel metabotropic glutamate receptor mGluR5 coupled to inositol phosphate/Ca2+ signal transduction. J Biol Chem (1992) 2.21
The metabotropic glutamate receptors, mGluR2 and mGluR3, show unique postsynaptic, presynaptic and glial localizations. Neuroscience (1996) 2.19
Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology (2001) 2.18
The group I mGlu receptor agonist DHPG induces a novel form of LTD in the CA1 region of the hippocampus. Neuropharmacology (1998) 2.16
The fragile X premutation: into the phenotypic fold. Curr Opin Genet Dev (2002) 2.15
Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc Natl Acad Sci U S A (1998) 2.14
Mutation of the Ca2+ channel beta subunit gene Cchb4 is associated with ataxia and seizures in the lethargic (lh) mouse. Cell (1997) 2.13
Repetitive self-grooming behavior in the BTBR mouse model of autism is blocked by the mGluR5 antagonist MPEP. Neuropsychopharmacology (2009) 2.10
Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain. Neurosci Lett (1993) 2.10
Adenosine A2A receptors are essential for long-term potentiation of NMDA-EPSCs at hippocampal mossy fiber synapses. Neuron (2008) 2.09
Postsynaptic induction and presynaptic expression of hippocampal long-term depression. Science (1994) 2.09
Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse (1987) 2.08
Noradrenaline modulates transmission at a central synapse by a presynaptic mechanism. Neuron (2007) 2.00
Preferential effects of the metabotropic glutamate 2/3 receptor agonist LY379268 on conditioned reinstatement versus primary reinforcement: comparison between cocaine and a potent conventional reinforcer. J Neurosci (2004) 1.99
Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. Proc Natl Acad Sci U S A (2003) 1.98
Presynaptic glutamate receptors: physiological functions and mechanisms of action. Nat Rev Neurosci (2008) 1.96
Sequence of abnormal dendritic spine development in primary somatosensory cortex of a mouse model of the fragile X mental retardation syndrome. Am J Med Genet A (2005) 1.90
Metabotropic glutamate receptors. Cell Tissue Res (2006) 1.89
Metabotropic glutamate receptor subtype 5 antagonists MPEP and MTEP. CNS Drug Rev (2006) 1.86
Metabotropic glutamate 2/3 receptors in the ventral tegmental area and the nucleus accumbens shell are involved in behaviors relating to nicotine dependence. J Neurosci (2007) 1.85
Long-term potentiation selectively expressed by NMDA receptors at hippocampal mossy fiber synapses. Neuron (2008) 1.83
ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. J Pharmacol Exp Ther (2008) 1.81
Induction of LTP in the hippocampus needs synaptic activation of glutamate metabotropic receptors. Nature (1993) 1.81
Impairment of hippocampal mossy fiber LTD in mice lacking mGluR2. Science (1996) 1.81
Adult fragile X syndrome. Clinico-neuropathologic findings. Acta Neuropathol (1985) 1.80
Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: differential location relative to pre- and postsynaptic sites. Neuroscience (2001) 1.80
Activation of group II metabotropic glutamate receptors in the nucleus accumbens shell attenuates context-induced relapse to heroin seeking. Neuropsychopharmacology (2005) 1.79
Differential plasma membrane distribution of metabotropic glutamate receptors mGluR1 alpha, mGluR2 and mGluR5, relative to neurotransmitter release sites. J Chem Neuroanat (1997) 1.76
The group II metabotropic glutamate receptor agonist, LY379268, inhibits both cocaine- and food-seeking behavior in rats. Psychopharmacology (Berl) (2006) 1.74
Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain (2002) 1.71
Functional Interaction Between NMDA and mGlu5 Receptors: Effects on Working Memory, Instrumental Learning, Motor Behaviors, and Dopamine Release. Neuropsychopharmacology (2004) 1.71
G protein betagamma directly regulates SNARE protein fusion machinery for secretory granule exocytosis. Nat Neurosci (2005) 1.69
Gbetagamma acts at the C terminus of SNAP-25 to mediate presynaptic inhibition. Nat Neurosci (2005) 1.65
Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons. Neuroscience (2001) 1.64
The pipeline and future of drug development in schizophrenia. Mol Psychiatry (2007) 1.63
The functional anatomy of disorders of the basal ganglia. Trends Neurosci (1995) 1.62
Protein translation in synaptic plasticity: mGluR-LTD, Fragile X. Curr Opin Neurobiol (2009) 1.61
Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J Pharmacol Exp Ther (2006) 1.60
Cellular localization of a metabotropic glutamate receptor in rat brain. Neuron (1992) 1.60
mGluR5 antagonism attenuates methamphetamine reinforcement and prevents reinstatement of methamphetamine-seeking behavior in rats. Neuropsychopharmacology (2008) 1.57
Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry (2008) 1.57
Activation of group II metabotropic glutamate receptors attenuates both stress and cue-induced ethanol-seeking and modulates c-fos expression in the hippocampus and amygdala. J Neurosci (2006) 1.55
Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039). J Pharmacol Exp Ther (2008) 1.55
Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse. J Neurosci (2003) 1.55
Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats. J Neurophysiol (2004) 1.55
Peripheral group I metabotropic glutamate receptors modulate nociception in mice. Nat Neurosci (2001) 1.54
Social behavior deficits in the Fmr1 mutant mouse. Behav Brain Res (2005) 1.54
European health systems and cancer care. Ann Oncol (2003) 1.27
Stress sensitivity and resilience in the chronic mild stress rat model of depression; an in situ hybridization study. Brain Res (2007) 1.17
Acute and long-term treatments with the selective serotonin reuptake inhibitor citalopram modulate the HPA axis activity at different levels in male rats. J Neuroendocrinol (1999) 0.89
Insulin-like growth factor-I and its receptor in the frontal cortex, hippocampus, and cerebellum of normal human and alzheimer disease brains. Synapse (2000) 0.86
Desensitisation of 5-HT autoreceptors upon pharmacokinetically monitored chronic treatment with citalopram. Eur J Pharmacol (2000) 0.82
Monoaminergic dysregulation in glutathione-deficient mice: possible relevance to schizophrenia? Neuroscience (2005) 0.81
Mode of action of lithium on the catalytic unit of adenylate cyclase from rat brain. Pharmacol Toxicol (1987) 0.80
Increased adenylyl cyclase type 1 mRNA, but not adenylyl cyclase type 2 in the rat hippocampus following antidepressant treatment. Eur Neuropsychopharmacol (2000) 0.79
Involvement of hippocampal neuropeptide Y in mediating the chronic actions of lithium, electroconvulsive stimulation and citalopram. Neuropharmacology (2000) 0.79
Chronic treatment with citalopram induces noradrenaline receptor hypoactivity. A microdialysis study. Eur J Pharmacol (1996) 0.78
Extracellular levels of neuropeptide Y are markedly increased in the dorsal hippocampus of freely moving rats during kainic acid-induced seizures. Brain Res (1998) 0.78
On the involvement of a tonic dopamine D2-autoinhibition in the regulation of pulse-to-pulse-evoked dopamine release in the rat striatum in vivo. Naunyn Schmiedebergs Arch Pharmacol (1997) 0.78
Chronic antidepressant treatments decrease pro-opiomelanocortin mRNA expression in the pituitary gland: effects of acute stress and 5-HT(1A) receptor activation. J Neuroendocrinol (2001) 0.78
Altered protein phosphorylation in the rat brain following chronic lithium and carbamazepine treatments. Eur Neuropsychopharmacol (1997) 0.78
Is an ephedrine caffeine treatment contraindicated in hypertension? Int J Obes Relat Metab Disord (1997) 0.77
Effects of lithium on calmodulin-stimulated adenylate cyclase activity in cortical membranes from rat brain. Pharmacol Toxicol (1987) 0.77
Effects of Li+ transport and intracellular binding on Li+/Mg2+ competition in bovine chromaffin cells. Biochim Biophys Acta (2004) 0.76
Li influx and binding, and li/mg competition in bovine chromaffin cell suspensions as studied by li NMR and fluorescence spectroscopy. Met Based Drugs (2000) 0.76
Abnormal protein phosphorylation in post-mortem brain tissue from bipolar patients. J Neural Transm (Vienna) (2000) 0.75
The effect of acute citalopram on extracellular 5-HT levels is not augmented by lithium: an in vivo microdialysis study. Brain Res (2000) 0.75
Morphine-6-glucuronide and morphine: mu-opioid receptor binding and effects on dopamine-sensitive adenylate cyclase in striatum. Pharmacol Toxicol (1991) 0.75
N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline studies on the role of 5-HT1A and 5-HT2 receptors in mediating foot-shock-induced ultrasonic vocalisation in adult rats. Eur Neuropsychopharmacol (1999) 0.75
Endogenous neurotensin down-regulates dopamine efflux in the nucleus accumbens as revealed by SR-142948A, a selective neurotensin receptor antagonist. J Neurochem (2001) 0.75
D-fenfluramine activates rat oxytocinergic and vasopressinergic neurons through different mechanisms. Brain Res (1999) 0.75
[Is Letigen contraindicated in hypertension? A double-blind, placebo controlled multipractice study of Letigen administered to normotensive and adequately treated patients with hypersensitivity]. Ugeskr Laeger (1998) 0.75
The effect of acute and chronic lithium on forskolin-induced reduction of rat activity. J Neural Transm (Vienna) (1997) 0.75